Skip to main content

Table 1 Concordance of result information between ClinicalTrials.gov and corresponding publications for phase III trials published in high-impact journals between January 1, 2016, and June 30, 2017

From: Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA

Result informationb,c Trials reporting results in both sources, no. (%) Result information in both sources
Concordant, no. (%) Discordant, no. (%) Cannot be compared, no. (%)
Cohort characteristics
 Completion rate 94 (100) 69 (73) 22 (23) 3 (3)
 Age distribution 93 (99) 70 (75) 20 (22) 3 (3)
 Sex distribution 89 (95) 67 (75) 19 (21) 3 (3)
 Race/ethnicity distribution 35 (37) 23 (66) 12 (34) 0
Trial intervention 94 (100) 83 (88) 11 (12) 0
Primary efficacy endpointa 94 (100) 70 (74) 20 (21) 4 (4)
Serious adverse events 93 (99) 41 (44) 24 (26) 28 (30)
  1. aTotal number of primary efficacy endpoints reported on ClinicalTrials.gov = 128 compared to publications = 112
  2. bTotal percentage of trials with at least one discrepancy across all categories = 87%
  3. cTotal percentage of trials with at least one discrepancy across all categories excluding race = 74%